5. Access & Practical Realities

Efficacy evidence is only half the picture. What a person can actually obtain — on a public health system, on private prescription, or by workaround — depends on drug registration status, subsidy listings, prescriber gatekeeping, and equipment funding rules that vary enormously by country. This section covers Australia in detail (with South Australia-specific notes), then contrasts the USA, UK, and Germany/EU as reference points, since Australian policy in this area (particularly home oxygen) does not track any of them cleanly.

5.1 Australia

5.1.1 The one-paragraph summary (South Australia)

For a chronic CH patient in South Australia, the blunt reality verified below is: there is no PBS listing for oxygen, no PBS or state-funded home-oxygen pathway for cluster headache, and no PBS listing for injectable or nasal sumatriptan. Oxygen for CH in SA is effectively a private, self-funded arrangement with a gas supplier on a doctor’s prescription. Of the five treatments in the brief, only oral sumatriptan tablets, oral zolmitriptan tablets and verapamil are PBS-subsidised — and the triptan listings are restricted to migraine, not cluster headache. Galcanezumab (Emgality) is PBS-listed only for treatment-resistant migraine. gammaCore is TGA-approved for CH but has no published price and no PBS/Medicare subsidy that I could find.

---

5.1.2 High-flow oxygen access in Australia

1.2.1 What the clinical literature says you need

Australian Prescriber’s CH review specifies 100% oxygen at 7–12 L/min for 15 minutes via a non-rebreather mask, with 78% of patients pain-free at 15 minutes versus 20% on placebo, and notes plainly that “Oxygen may be ordered from medical gas supply companies in Australia with a prescription.” It also states that “the drugs used for the acute and preventive treatment of cluster headache are off label, but supported by clinical evidence” (Australian Prescriber — Cluster headache in adults). peer-reviewed

The Sydney Headache Centre (Dr Ron Granot) puts the practical dose higher — 12–15 L/min via non-rebreather for 15–20 minutes, first-line — and states it “requires oxygen cylinder at home (respiratory equipment provider arranges)” (Sydney Headache Centre). peer-reviewed (clinician-authored clinical page)

Oxygen is contraindicated in active smokers and in type 2 respiratory failure (Australian Prescriber). peer-reviewed

1.2.2 Is oxygen on the PBS? — verified: NO

I searched the PBS medicine database directly (pbs.gov.au, site last updated 1 August 2026):

• Search term “oxygen” → “No results!”
• Search term “cluster headache” → “No results!”

(PBS medicine search) official / policy

Conclusion: medical oxygen is not a PBS-listed item in Australia, and no PBS restriction anywhere in the schedule is indexed to “cluster headache.” This is a verified negative, not an omission.

1.2.3 The South Australian state-funded pathway — and why CH doesn’t fit it

SA Health runs a state-funded Home Oxygen Therapy program. Its published rules:

• “To access home oxygen you will need to be reviewed by a respiratory specialist who will determine whether you may benefit from home oxygen therapy and meet the Thoracic Society of Australia & New Zealand (TSANZ) Home Oxygen Guidelines.” Referrals go to Local Health Network program coordinators (SA Health — Home Oxygen Therapy). official / policy
• “Respiratory Physicians are the only medical team eligible to prescribe government funded home oxygen across South Australia.” Funding is for the patient’s residence only (not aged care, rehab or hospital-in-the-home); DVA Gold Card holders are funded by DVA instead. Ongoing funding requires respiratory specialist review at 4–6 weeks and then at least every 12 months (SA Health — Home Oxygen Adult Clinical Prioritisation Criteria). official / policy
• Every listed indication is hypoxaemia-based — chronic hypoxaemia, acute hypoxaemia, exertional hypoxaemia, nocturnal hypoxaemia, emergency and palliative supply. Cluster headache does not appear. Explicit exclusions include current smokers/vapers (4 weeks’ cessation required) and “dyspnoea with PaO2 ≥60 mmHg or SpO2 ≥90% on room air” (SA Health CPC). official / policy
• SA Health’s patient booklet reinforces it: oxygen is funded where “all other treatment for a condition has been given and the amount of oxygen in the blood still remains below a certain level,” assessed by a respiratory or sleep specialist, with annual review and a minimum four-week smoking cessation requirement. Conditions named are heart problems, lung problems, sleep-related conditions and underdeveloped lungs in premature babies. Cluster headache is not mentioned anywhere in the booklet (SA Health Home Oxygen Therapy Booklet, PDF). official / policy

INFERENCE (clearly labelled): Because SA’s funded criteria are entirely hypoxaemia-based and CH patients are by definition normoxaemic between and during attacks, a CH patient in SA would not meet SA Health’s criteria for state-funded home oxygen. SA Health does not state “cluster headache is excluded” in so many words — it simply has no non-hypoxaemic indication. I could not find any SA Health document that either grants or explicitly refuses oxygen funding for CH: UNKNOWN — not verified whether an SA respiratory physician has ever obtained funded supply for a CH patient by exception.

1.2.4 The private pathway (what actually happens in SA)

BOC Australia’s home medical oxygen therapy page states: “If you are a self-funded or private patient, you along with your doctor will need to complete a referral form” (emailed to healthcare@boc.com), and “As a private patient you will be responsible to pay for your own HMOT equipment.” Phone 1800 050 999 (BOC Australia — Oxygen therapy). official / policy (supplier policy)

So the realistic SA sequence is: GP or neurologist writes a prescription/referral for medical oxygen → you contact a medical gas supplier (BOC, Supagas, Air Liquide) directly → you rent the cylinder(s) and regulator and pay per refill. No respiratory physician sign-off is required for the private route — that requirement attaches to government-funded supply only.

BOC/Supagas/Air Liquide published prices for CH-sized private supply: UNKNOWN — not verified. None of these suppliers publishes a public price list for private home oxygen; pricing is quoted per account. Community-reported figures are in §1.5.

1.2.5 Rebates and payments you may still be able to claim (SA)

• SA electricity concession for oxygen concentrators: a 50% electricity rebate for pensioners/health care card holders — but SA Health states it applies to people “receiving state-funded home oxygen therapy.” Contact Concessions SA on 1800 307 758 or concessions@sa.gov.au (SA Health — Home Oxygen Therapy Rebate). official / policy INFERENCE: a privately funded CH patient using cylinders (not a concentrator) would not qualify.
• The same page notes DVA payments, that “some private health insurers provide subsidies for oxygen equipment,” and the federal Essential Medical Equipment Payment administered by Services Australia (SA Health). official / policy Whether any Australian private health fund actually pays for CH oxygen: UNKNOWN — not verified.

1.2.6 How other Australian states compare (useful if you ever move, and as evidence of a national pattern)

State/scheme	Who can prescribe	Eligibility	CH covered?
SA Health	Respiratory physicians only, for government-funded supply (CPC)	TSANZ hypoxaemia guidelines	Not listed
QLD — MASS	Thoracic physician, specialist physician, oncologist, palliative care physician, or respiratory nurse practitioner with specialist endorsement; GP with specialist endorsement in rural/remote areas. Adults reassessed at 4 months then annually (Queensland Health MASS)	“MASS does not subsidise oxygen for dyspnoea without hypoxaemia”; not for current smokers; not for portable community access except in special circumstances	Cluster headache is not mentioned; eligibility for CH is not stated (MASS)
VIC — SWEP Domiciliary Oxygen Program	Physician-prescribed	Explicitly ineligible if “the consumer does not fall within the Thoracic Society Guidelines”, if the problem is not permanent, or if oxygen is for “occasional use”; PaO2 ≤55 mmHg, or 56–59 mmHg with hypoxic organ damage; 6–8 weeks’ smoking cessation (SWEP Domiciliary Oxygen Prescriber Manual, PDF)	Not eligible — CH oxygen is by definition intermittent/“occasional use” and non-hypoxaemic (INFERENCE)
NSW — EnableNSW	—	Page blocked to automated retrieval	UNKNOWN — not verified (EnableNSW respiratory)
DVA	—	Domiciliary Medical Oxygen Therapy under the Rehabilitation Appliances Program (DVA DMOT)	UNKNOWN — not verified whether CH is an accepted DVA indication

QLD MASS is worth knowing for its concrete supply limits: Package 5 = 1 × ‘E’ size cylinder, maximum 4 filled cylinders per month; Package 4 = concentrator + one ‘E’ cylinder filled once every three months; suppliers are Air Liquide, Heeson Medical and Supagas (MASS oxygen packages and suppliers). official / policy Four E cylinders a month is far below what a chronic CH patient with multiple daily attacks would use — see the community reports in §1.5.

The pattern across every Australian state scheme I could verify is the same: funded home oxygen is gated on hypoxaemia and TSANZ long-term-oxygen-therapy criteria, which cluster headache does not meet.

---

5.1.3 Drug and device approval/subsidy status in Australia — verified item by item

All PBS statements below were checked directly on pbs.gov.au in August 2026 (schedule last updated 1 August 2026).

Sumatriptan

Form	TGA status	PBS status
Oral tablets	Registered	PBS-listed. Three items: 10694W (50 mg fast-disintegrating, 4), 1849H (50 mg tablet, 4), 8144P (50 mg tablet, 2). Restricted Benefit; indication: “Migraine attack.” DPMQ $20.64 / $20.04 (8144P) and $20.41 (1849H) (PBS item 8144P, PBS item 1849H) official / policy
Injection 6 mg SC	TGA-registered as CLUSTRAN, ARTG 209316, “indicated for the acute treatment of cluster headaches” (TGA ARTG 209316) official / policy	NOT on the PBS. The PBS sumatriptan search returns one drug and three items — all oral tablets. No injection item exists. The healthdirect brand page for Clustran carries no “available on the PBS” flag, unlike PBS-listed brands (healthdirect — Clustran). Private script, full price.
Nasal spray	Discontinued in Australia. Aspen Pharma discontinued the nasal spray and injectable Imigran at the end of 2023 because its supplier stopped manufacturing and “after an extensive search they have been unable to source an alternative manufacturer.” “As they were the only nasal spray supplier, there are currently no suppliers of this form in Australia.” A compounding pharmacy may be able to prepare one on request (Migraine Australia — Imigran discontinuations) official / policy (patient-org reporting confirmed by sponsor)	N/A

Migraine Australia summarises the triptan situation bluntly: “All five are available on the PBS, but not all preparations are covered by the PBS… you can get the tablet affordably but not the injection” (Migraine Australia — Triptans). official / policy

Clustran retail price: UNKNOWN — not verified. Chemist Warehouse and Pharmacy Online both list the product (2 pre-filled pens, 6 mg/0.5 mL) but neither publishes a price; Pharmacy Online shows “Our Price $0.00” and requires a valid Australian prescription before shipping (Pharmacy Online — Clustran, Chemist Warehouse — Clustran). Ring a pharmacy for a quote — this is a genuine gap in public information.

Zolmitriptan

• PBS: one item only — 8266C, zolmitriptan 2.5 mg tablet × 2, DPMQ $25.68, with a $4.50 brand premium on Zomig (PBS item 8266C). official / policy
• Intranasal zolmitriptan — the formulation with the CH evidence base — is currently not available in Australia (Australian Prescriber). peer-reviewed Corroborated: “None of the other triptans are currently available in a non-oral formulation in Australia” (Migraine Australia). official / policy

Verapamil (the mainstay CH preventive)

• PBS General Schedule, cardiovascular body system, with no restriction text — i.e. unrestricted. Items include 1241H (240 mg modified-release × 30, DPMQ $20.92), 1250T (80 mg × 100, $20.41) and 2208F (180 mg MR × 30, $19.13) (PBS verapamil items). official / policy
• Practical read: because verapamil is unrestricted on the PBS, a GP can prescribe it at PBS price for CH without an authority, even though the use is off-label. This is the single cheapest and most accessible piece of the standard CH regimen in Australia. Note the off-label caveat from Australian Prescriber. peer-reviewed

Galcanezumab (Emgality)

• TGA Product Information: “EMGALITY is indicated for the prophylaxis of migraine in adults.” No cluster headache indication (TGA AusPAR PI, PDF). official / policy
• PBS: items 12469G (continuing) and 12478R (initial), Authority Required (STREAMLINED), restriction number 14563, indication “Treatment-resistant migraine.” DPMQ $523.36, patient charge $25.00 (PBS item 12469G); listed 1 June 2021 (PBS medicine status). official / policy
• Bottom line: no PBS pathway for Emgality in cluster headache in Australia. Off-label private supply would be at roughly the $523 DPMQ level per month, unsubsidised. (Note the 300 mg CH dose used in the US is 2.5× the 120 mg migraine dose, so real cost would be higher — see §2.3.)

gammaCore (non-invasive vagus nerve stimulator)

• ARTG 355575. The TGA advertising permission (dated 23 October 2023, last updated 10 September 2024) states: “In Australia, GammaCore is indicated for the treatment and/or prevention of primary headache conditions (such as migraine and cluster headache) in adults” and that it is “available in Australia on authorisation by a registered healthcare professional” (TGA advertising permission — Medistar/gammaCore). official / policy
• The Australian distributor (Medistar) requires an Authorisation and Consent Form from a healthcare professional; the device runs on refill cards that load days of therapy, and states the HCP provides initial and ongoing costs — no prices are published (Medistar — gammaCore for patients). official / policy
• PBS/Medicare/Prostheses List subsidy for gammaCore in Australia: UNKNOWN — not verified. It does not appear in the PBS medicine database (which covers medicines, not devices), and I found no MBS item or Prostheses List entry for it. Australian price: UNKNOWN — not verified. For scale, the NHS-facing price is £625 per 93 days ex-VAT (§4.4).

Australia summary table

Treatment	TGA-approved for CH?	PBS-subsidised for CH?	What you actually pay
High-flow oxygen	Not a PBS/TGA-listed medicine in Australia; supplied on prescription by gas companies	No — “oxygen” returns no results on the PBS	Full private cost (see §1.5 for community figures)
Sumatriptan tablets	Registered	Yes — but restricted to “Migraine attack”	~$20 DPMQ (general)
Sumatriptan injection (Clustran)	Yes — CH is the labelled indication	No	Private script, price not published
Sumatriptan nasal	No supplier in Australia	No	N/A
Zolmitriptan tablets	Registered	Yes (item 8266C)	$25.68 DPMQ
Zolmitriptan nasal	Not available in Australia	No	N/A
Verapamil	Registered (cardiac indications; CH use is off-label)	Yes — unrestricted	~$19–21 DPMQ
Galcanezumab (Emgality)	Migraine prophylaxis only	Only for treatment-resistant migraine	$25 co-pay if migraine criteria met; ~$523+/month private for CH
gammaCore	Yes — CH named in the TGA-permitted indication	Not found	Unknown; HCP-quoted

---

5.1.4 Who to see in Australia

• The PBS/state rules mean the specialist you need for oxygen and the specialist you need for CH are different people. A neurologist or headache specialist diagnoses and manages CH and writes the oxygen prescription for a private supplier; a respiratory physician is the only person who can access government-funded oxygen in SA — for a hypoxaemia indication you won’t have (SA Health CPC). official / policy
• Migraine & Headache Australia (a division of the Brain Foundation) is the closest thing to a national headache patient body and has a CH page — but that page carries no access, cost or oxygen-supply information (Migraine & Headache Australia — Cluster Headache, Brain Foundation). official / policy
• Is there an Australian equivalent of Clusterbusters or OUCH-UK? After targeted searching: no registered Australian CH-specific advocacy charity was found. What exists is (a) Migraine & Headache Australia, (b) Migraine Australia (which does publish concrete access information — see Triptans and Discontinuations), (c) a patient-run site Cluster Headaches Australia (clusterheadaches.com.au), which is informational — it describes 100% oxygen via non-rebreather at “typically 12–15 litres per minute” and cites the 2023 European Academy of Neurology guideline, but it is not an advocacy organisation with an access-navigation service (Cluster Headaches Australia) community report, and (d) the “Australia New Zealand Cluster Headache” Facebook support group (see §1.5). A directory of world CH support groups lists exactly these two Australian entries and no advocacy charity (myclusters.nl — Patient support groups around the world). community report

---

5.1.5 Community knowledge on navigating access — Australia community report

Everything in this section is anecdotal patient report. None of it is verified policy. Some of it directly contradicts other reports, and I flag that where it happens.

The 2017 change.org petition (created 26 September 2017, 3,667 signatures) to the Minister for Health is the clearest documented statement of the Australian access problem from patients themselves: “Proven front line abortives for this condition include Sumatriptan injections and 100% Medical grade oxygen. Both of which are not covered under the PBS Scheme and have high costs.” It reports oxygen “costing in excess of $300 a month”, that “medical grade oxygen requires a prescription… generally supplied by a neurologist”, names BOC and Supagas as suppliers, and describes neurologist wait times of weeks to months at significant cost (change.org petition). community report — Note this petition’s PBS claims match what I independently verified above, which raises its credibility on the cost figures.

Reddit r/ClusterHeadaches “Oxygen and Medicare” — an Australian thread (link) community report:

• Explicit conflict: the OP claimed “Medicare covers the rental of medical oxygen cylinders for 36 months”, while another commenter replied “I am not aware of any Medicare rebate.” My verification supports the sceptic: there is no MBS/PBS oxygen item I could find, and the PBS returns no results for oxygen. Treat the “36 months” claim as unverified and probably wrong (it resembles the US Medicare DME 36-month oxygen rental rule, which does exist under US Medicare — see §2.1). community report + INFERENCE
• OP noted “My Supagas paperwork lacks item numbers or claim details” — consistent with there being nothing to claim.
• Costs reported: ~$15/month for a regulator; $188 for an E and D cylinder; Air Liquide $58.80 per E-size bottle when self-collected; a Mega Medical “Oxygen Demand Valve Resuscitator plus Regulator Series O” at roughly $800 for the pair. An E cylinder was said to last about a week at CH usage rates.
• QLD MASS supplies 4 E cylinders per month and this was described as insufficient — which matches the official MASS Package 5 limit verified above (MASS packages).
• Practical name worth knowing: “Kay Tebby at Supagas” was described as having helped many Australians get supply set up, and as being active in the “Australia New Zealand Cluster Headache” Facebook support group. I could not independently verify this person’s role — UNKNOWN — not verified — but it is the single most actionable lead in the Australian community material.

An Australian CH Facebook group post states that “if you’re in Australia and seeking medical oxygen for cluster… a doctor’s prescription is required” (Facebook group post). community report — I could not fetch the full post content (Facebook blocks retrieval), so treat the detail beyond that sentence as unverified.

Sydney anecdote on r/clusterheads describing local oxygen access (thread), and general community flow-rate consensus of 12–15 L/min, with 15–20 L/min described as ideal (r/clusterheads oxygen thread, oxygen therapy thread). community report — note the community flow rate is higher than the 7–12 L/min in Australian Prescriber. That’s a real, honest conflict between community practice and the Australian published guidance; the international literature and Clusterbusters both sit at 12–15 L/min.

Practical Australian checklist distilled from the above (community-derived, not official):

1. Get a neurologist/headache specialist diagnosis in writing — it’s what suppliers and any funding conversation will hinge on.
2. Ask for the oxygen prescription to specify 100% oxygen, 12–15 L/min, via non-rebreather mask, 15–20 minutes per attack, as needed for cluster headache, and to request two large cylinders plus a portable so you never run empty mid-bout.
3. Check the regulator’s maximum flow before accepting it — many standard regulators cap at 15 L/min or lower, and a cap below 12 L/min makes the therapy fail.
4. Do not accept a concentrator as a substitute for CH abortive use (see §5).
5. Contact suppliers directly (BOC 1800 050 999 / referral form; Supagas; Air Liquide) and ask about self-collection, which community reports say is materially cheaper per refill.
6. Verapamil is unrestricted on the PBS — that part is cheap and your GP can handle it.
7. Ask your pharmacy for a Clustran price before you need it, and ask about a compounded sumatriptan nasal spray if injection cost is prohibitive (Migraine Australia).

---

5.2 United States

5.2.1 Oxygen — the big policy change of 2021

For decades US Medicare explicitly did not cover home oxygen for cluster headache under NCD 240.2.2.

On 2 July 2021 CMS issued a proposed decision memo (CAG-00296R2) to remove NCD 240.2.2 (Home Oxygen Use to Treat Cluster Headache) and modify NCD 240.2. Of 200 public comments, 188 were CH-related and all were supportive; the request came from the Alliance for Headache Disorders Advocacy (CMS proposed decision memo CAG-00296R2). official / policy

The final decision was published 27 September 2021: CMS removed NCD 240.2.2 and revised NCD 240.2, so coverage decisions for oxygen in these circumstances now sit with the Medicare Administrative Contractors (MACs) rather than being nationally barred (Noridian DME MAC — Oxygen LCD L33797 update). official / policy The relevant LCD, L33797 Oxygen and Oxygen Equipment, confirms the September 27 2021 decision memo “Home use of Oxygen and Home Oxygen Use to Treat Cluster Headaches” in its history, is effective for services on or after 1 April 2023, and reimburses oxygen as a bundled monthly rental payment with a higher stationary-system allowance for flow rates above 4 L/min (CMS LCD L33797). official / policy

The earlier, superseded national non-coverage memo is at CMS NCA 244. official / policy

Important caveat, stated honestly: removing the national non-coverage rule is not the same as creating national coverage. Whether any specific MAC now routinely pays for CH oxygen, and on what documentation: UNKNOWN — not verified. The current CMS NCD 240.2 record page simply directs readers to their MAC (CMS NCD “Home Use of Oxygen”). official / policy In practice most US CH patients are under commercial insurance, not Medicare, and plan-by-plan variation is the norm.

5.2.2 Sumatriptan in the USA

• FDA label for Imitrex injection: indicated for the acute treatment of migraine and of cluster headache — the on-label status Australia lacks for the PBS but shares via Clustran (FDA Imitrex injection label, PDF). official / policy
• Cash pricing for generic sumatriptan subcutaneous 6 mg/0.5 mL is listed at $14.19 per 0.5 mL unit; roughly $65.38–$69.95 for a 2-pack, or $44.75–$53.95 for a 5-pack (USD; the aggregator does not date these) (Drugs.com price guide — sumatriptan). official / policy (commercial price aggregator — treat as indicative, not authoritative). This makes generic US injectable sumatriptan dramatically cheaper than the Australian private route, which is a genuine and unflattering comparison for Australia.

5.2.3 Galcanezumab (Emgality) in the USA

• FDA-approved for both preventive treatment of migraine and treatment of episodic cluster headache (FDA Emgality label, PDF). official / policy This is the crucial divergence: the US has an on-label CH indication that neither Australia nor the EU has.
• Cash cost is roughly $700–$981 USD per month depending on source, with the CH dose being 300 mg versus 120 mg for migraine prevention (SingleCare, MedFinder). official / policy (commercial sources — indicative). Lilly’s commercial-insurance savings card advertises “as little as $35” for up to 12 months (Emgality Savings Card). official / policy Prior-authorisation friction and denials are routinely reported (MedFinder). community report

5.2.4 gammaCore in the USA

FDA-cleared for episodic cluster headache (K211856), prescription required; reviewed for efficacy, safety and economic burden in episodic and chronic CH (AJMC review of nVNS/gammaCore). peer-reviewed US list price and insurance coverage: UNKNOWN — not verified.

5.2.5 Verapamil in the USA

Generic, widely available, off-label for CH. UNKNOWN — not verified for specific US formulary tiers.

---

5.3 United Kingdom (the best-organised system of the four)

5.3.1 Oxygen — a dedicated CH pathway exists

NHS England’s “Good HOOF guide” (4 November 2020) explicitly supports non-specialist primary care and out-of-hours teams ordering home oxygen for palliative and cluster headache patients, “normally following a consultant recommendation and not already under the care of a HOS-AR team” (NHS England — Good HOOF guide); the Home Oxygen Order Form (HOOF) documents are at NHS England — HOOF letters and guidance. official / policy

OUCH(UK) — the UK CH charity — documents the patient-side mechanics: in England and Wales your GP can prescribe; you can download a part-completed HOOF from OUCH’s downloads; the GP completes the Home Oxygen Consent (HOC) and Initial Home Oxygen Risk Mitigation (IHORM) forms and submits the HOOF through the oxygen company portal; and “it is specifically laid down in the Home Oxygen Assessment Service (HOAS) specification that GPs can prescribe oxygen for CH sufferers for pain relief.” OUCH puts response to oxygen at around 80% and distinguishes standard high-flow (SBOT) from demand valve systems (OUCH(UK) — Oxygen for CH 2023, PDF). community report (patient charity guidance, corroborated by NHS documents)

Local implementation is concrete. Nottinghamshire APC’s Home Oxygen Pathway for Cluster Headaches v2.1 (reviewed November 2025) requires newly diagnosed patients to have neurologist confirmation; the neurologist completes the IHORM, HOCF and HOOF and sends them direct to BOC via www.bochop.co.uk; existing users need a GP referral to the Home Oxygen Service for a home safety assessment (Nottinghamshire APC pathway, PDF). official / policy There is also dedicated London cluster headache guidance for GPs and neurologists (Sept 2021). official / policy

Cost to the UK patient: home oxygen is supplied through the NHS home oxygen service at no charge to the patient. I did not find a single NHS page stating that in one sentence, so: the absence of a patient charge is implied by the HOOF/contracted-supplier model rather than explicitly verified — INFERENCE.

5.3.2 Drugs in the UK

• Sumatriptan injection is licensed in the UK with cluster headache in its indication (UK SmPC — sumatriptan injection). official / policy
• NHS prescriptions in England cost £9.90 per item, charged per item not per prescription; a Prescription Prepayment Certificate (PPC) is cheaper for people needing many items (NHS — prescription charges). official / policy (Prescriptions are free in Scotland, Wales and Northern Ireland — UNKNOWN — not verified from a primary source in this pass.)
• Verapamil, zolmitriptan: available on NHS prescription at the standard charge. Specific NICE guidance on verapamil dosing for CH: UNKNOWN — not verified in this pass (NICE CKS covers CH but was not fetched).
• Galcanezumab for CH: not licensed in the EU/UK for CH (see §4.2); UK-specific NICE appraisal for CH: UNKNOWN — not verified.

5.3.3 gammaCore — the UK is the only country with a positive HTA

NICE published HTG533 “gammaCore for cluster headache” on 3 December 2019, replacing MIB162 and MTG46, concluding “Evidence supports the case for adopting gammaCore to treat cluster headache in the NHS” and that “gammaCore should be offered in addition to standard care.” Costs: free of charge for the first 3 months (93 days), then £625 per 93 days excluding VAT; modelling estimates a £450 per person saving in the first year, largely from reduced subcutaneous sumatriptan use. NICE also records the funding reality: “It has been difficult for clinical services to get funding for gammaCore… the experts explained that they get it through individual patient funding requests to commissioners” (NICE HTG533, PDF). official / policy

---

5.4 European Union / Germany

5.4.1 Germany has the strongest oxygen position of any country reviewed

Germany is the only country found where oxygen is formally licensed as a medicine for cluster headache and the hardware is catalogued for that indication:

• BfArM approved “Sauerstoff, 100% Gas zur medizinischen Anwendung, druckverdichtet (Druckgasflaschen)” for the treatment of cluster headache on 14 December 2007, approval number 69557.00.00 (DMKG — Sauerstoffbehandlung bei Cluster-Kopfschmerz, PDF). official / policy
• In the statutory health insurers’ Hilfsmittelverzeichnis, the pressure regulator is listed under 14.24.05.0000 specifically for the indication cluster headache, and the oxygen cylinders themselves are consumables under 14.99.99.1 (DMKG — Empfehlungen Sauerstoff). official / policy
• “Die Kosten für die Sauerstoffbehandlung werden von den gesetzlichen Krankenkassen übernommen, dazu ist eine ärztliche Verordnung erforderlich” — the statutory health funds cover the cost of oxygen treatment; a medical prescription is required (DMKG PDF). official / policy
• The prescribing mechanics: for statutory-insured patients the doctor writes a Hilfsmittelrezept noting the required flow (7–15 L/min, approx. 15–20 min per attack) and the diagnosis; the patient takes it to a Sanitätshaus, which handles cost approval with the fund; in urgent cases contacting the fund directly saves time; “Nur noch in Ausnahmefällen kommt es in den letzten Jahren zu Rückfragen des Medizinischen Dienstes” (queries from the medical review service are now rare) (DMKG). official / policy
• DMKG’s model prescription is worth copying almost verbatim in any country: 1 × pressure regulator with a 0–15 L/min range (Hilfsmittel position 14.24.05.0), 2 × 10-litre 200 bar medical oxygen cylinders (14.99.99.1), 2 × non-rebreather masks, plus for mobile use an additional regulator and 2-litre cylinders (DMKG PDF). official / policy
• Two pointed pieces of German advice: “Nicht sinnvoll ist ein Attest eines Lungenfacharztes” — a certificate from a lung specialist is not useful — because “Diagnose und Therapie des Clusterkopfschmerzens gehört als primäres Kopfschmerzsyndrom in das neurologische Fachgebiet” (CH belongs to neurology, not respiratory medicine) (DMKG). official / policy This is the exact opposite of the South Australian gatekeeping model, where only respiratory physicians can access funded oxygen.
• German patient wiki guidance also warns that oxygen-conserving systems and concentrators, while appropriate for long-term oxygen therapy, are explicitly not appropriate for cluster headache (ck-wissen — Sauerstoff im Hilfsmittelverzeichnis). community report
• German patient co-payment amounts (the usual GKV Zuzahlung) for oxygen supply: UNKNOWN — not verified.

The German/DGN-DMKG guideline background confirms the clinical basis: oxygen inhalation efficacy proven in a placebo-controlled trial; subcutaneous sumatriptan 6 mg and nasal zolmitriptan 5–10 mg are the parenteral agents with the best acute efficacy (AWMF S1 guideline, Clusterkopfschmerz und trigeminoautonome Kopfschmerzen, PDF). peer-reviewed (note: this version is marked expired/abgelaufen — a newer DMKG guideline exists at dmkg.de)

5.4.2 Galcanezumab was REFUSED for cluster headache in the EU

The EMA’s CHMP refused the extension of the Emgality marketing authorisation to episodic cluster headache on 28 February 2020 (procedure EMEA/H/C/004648/X/0004), on the grounds that “superiority of galcanezumab compared with placebo in reducing the number of headache attacks within a cluster bout was not convincingly demonstrated” (EMA Q&A on refusal, PDF; European Commission community register; Emgality EPAR). official / policy German coverage of the refusal: Schmerzklinik Kiel. peer-reviewed (clinician-authored)

So: Emgality is on-label for episodic CH in the USA, refused for CH in the EU, and migraine-only in Australia. That is a genuine international regulatory conflict, and it is the honest answer to “why can’t I get Emgality for my clusters here.”

5.4.3 Other German/EU drug access

• Sumatriptan 6 mg subcutaneous is licensed and reimbursed in Germany; nasal zolmitriptan (5–10 mg) is available in Europe and is recommended in the German guideline (AWMF S1 guideline, PDF). peer-reviewed This is a formulation Australians simply cannot obtain (Australian Prescriber).
• Verapamil for CH in Germany is off-label, as everywhere; specific German Off-Label-Use reimbursement approval status: UNKNOWN — not verified.
• A German home-care supplier publishes a CH oxygen prescription template citing DMKG first-line status at 8–12 L/min of 100% oxygen via mask (OxyCare — Verordnung Cluster-Kopfschmerz, PDF). official / policy (supplier document)
• gammaCore reimbursement in Germany/EU: UNKNOWN — not verified.

---

5.5 Cross-Cutting Community Knowledge community report

Clusterbusters (US) publishes the most detailed practical oxygen guidance in the CH world:

• The prescription should read “12–15 lpm with a nonrebreather mask”, “as needed for cluster headaches” (Clusterbusters — Oxygen therapy for cluster headaches).
• 44% of oxygen users had to suggest oxygen to their doctors themselves — self-advocacy is the norm, not the exception (same source). citizen science (patient-org survey figure)
• Concentrators are “essentially useless” for aborting CH attacks, because they cannot deliver the required flow of 100% oxygen (same source). Corroborated independently by German patient guidance (ck-wissen).
• Ask for two or more large tanks plus a small portable; bring published studies to the appointment; consider changing doctors if refused (same source).
• Minimum 12–15 LPM, and most suppliers’ standard regulators cap at 15 LPM (Clusterbusters — oxygen resource).
• A demand valve delivery system costs around $350 or more; regulators rated to 15 lpm and above are sold by Linde Healthcare, Mada Medical and Flotec, and many patients buy them on eBay or Amazon (Clusterbusters knowledgebase). The same page notes some patients resort to welding oxygen because of insurance problems — recorded here as a documented community practice, not a recommendation.
• Clusterbusters also publishes a how-to guide to help providers successfully prescribe oxygen and a patient resources hub — both usable in Australia as documents to hand a reluctant GP.

Where the communities live: r/clusterheads and r/ClusterHeadaches on Reddit, the Clusterbuds and Clusterheads Discord servers, and country groups; for Australia specifically, the “Australia New Zealand Cluster Headache” Facebook group (myclusters.nl directory).

---

5.6 Side-by-Side Summary

	Australia (SA)	USA	UK	Germany/EU
Oxygen licensed/listed for CH	No — not on PBS at all	N/A (device benefit, not a drug listing)	N/A (HOOF system)	Yes — BfArM 69557.00.00 since 2007
Who prescribes CH oxygen	Any doctor for a private supply; respiratory physician for funded supply (which CH doesn’t qualify for)	Physician; MAC decides coverage	GP can prescribe (HOAS specification), usually after consultant recommendation	Neurologist; explicitly not a lung specialist
Who pays	You do	Medicare MAC discretion since Sept 2021; otherwise insurer	NHS	Statutory health funds (GKV)
Sumatriptan injection	TGA-approved for CH (Clustran) but not on PBS	On-label for CH; generic ~$65 USD/2-pack cash	Licensed for CH; £9.90 per item	Licensed and reimbursed
Nasal triptan for CH	None available in Australia	Available	Available	Nasal zolmitriptan available and guideline-recommended
Verapamil	PBS unrestricted (~$20)	Generic	NHS charge	Reimbursed (off-label)
Galcanezumab for CH	Migraine-only on PBS/TGA	FDA-approved for episodic CH	Not licensed for CH	EMA refused, Feb 2020
gammaCore	TGA-approved incl. CH; no subsidy found; price unpublished	FDA-cleared for episodic CH	NICE HTG533 supports adoption; £625/93 days after free 93 days	Unknown

The single most important honest finding for an Australian reader: Australia has the worst verified access position of the four jurisdictions for the two most effective acute CH treatments. Oxygen has no subsidy pathway at all, and the injectable triptan that is TGA-approved specifically for cluster headache is not on the PBS, while the nasal formulations have left the market entirely.

---

6. Treatment Decision Tree

The diagram below is a synthesis of the pathway implied by the guidance and trial designs cited in Sections 1–3 above (Australian Prescriber 2022, EAN 2023, and the EHF refractory-CH consensus), not a new clinical recommendation. It shows how acute, bridge, and preventive treatment are meant to interlock, and marks where Australian access rules (Section 5.1) create a gap between the “textbook” pathway and what is actually obtainable.

Reading the diagram against Australian reality: the biggest divergence between the textbook pathway and what is actually available sits at the very first box. Oxygen — the acute treatment with the strongest and longest-standing evidence base — has no PBS pathway in Australia and is not subsidised as a home medical device for CH (Section 5.1). Nasal and injectable triptan formulations used internationally for fast abortive treatment are largely unavailable or unsubsidised here too. That means many Australian chronic sufferers enter the “bridge → preventive” arm of the tree without the acute-treatment layer functioning as designed elsewhere, which in turn raises the practical stakes of getting bridge and preventive therapy right quickly.